YM155 (Sepantronium Bromide)

Catalog No.S1130

For research use only.

YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells. Phase 2.

YM155 (Sepantronium Bromide) Chemical Structure

CAS No. 781661-94-7

Selleck's YM155 (Sepantronium Bromide) has been cited by 155 publications

Purity & Quality Control

Choose Selective Survivin Inhibitors

Other Survivin Products

Biological Activity

Description YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells. Phase 2.
Targets
Survivin [1]
(HeLa-SURP-luc, CHO-SV40-luc cells)
0.54 nM
In vitro

YM155 is not sensitive to survivn gene promoter-driven luciferase reporter activity even at 30 μM. YM155 significantly inhibits endogenous survivin expression in PC-3 and PPC-1 human HRPC cells with deficient p53 through transcriptional inhibition of the survivin gene promoter. On the contrary YM155 shows no sufficient effect on protein expression of c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, α-actin, and β-tubulin at 100 nM. YM155 indicates great apoptosis in human cancer cell lines including PC-3 and PPC-1 with a concomitant increase in caspase-3 activity. YM155 potently inhibits human cancer cell lines (mutated or truncated p53) including PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5 and A375 with IC50 from 2.3 to 11 nM, respectively. [1] YM155 increases the sensitivity of NSCLC cells to γ-radiation. The combination of YM155 and γ-radiation increases both the number of apoptotic cells and the activity of caspase-3. YM155 delays the repair of radiation-induced double-strand breaks in nuclear DNA. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kasumi-1 NELMdJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTlO|IhcA>? MWPEUXNQ MWLJR|UxRTBwMEC5JOKyKDBwMECwPUDPxE1? NXyzNJRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OVk4OzFpPkK1OlU6PzNzPD;hQi=>
M-07e NILReHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:zO|IhcA>? M33rTmROW09? MWrJR|UxRTBwMESwJOKyKDBwMEGzJO69VQ>? NFi2PJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
THP-1 NHnGeVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWO3NkBp MmL2SG1UVw>? NXjWfJFtUUN3ME2wMlA2OSEEsTCwMlAyOyEQvF2= M323eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O|MyLz5{NU[1PVc{OTxxYU6=
CMK M3vhfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LDUFczKGh? NHHwPYpFVVOR MX;JR|UxRTBwMEWzJOKyKDBwMEC5JO69VQ>? NW\6OHk1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OVk4OzFpPkK1OlU6PzNzPD;hQi=>
MV4-11 M1\pcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfrUnBVPzJiaB?= NE\qTHhFVVOR NGD4VnNKSzVyPUCuNFU2KMLzIECuNFI5KM7:TR?= M2f1ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O|MyLz5{NU[1PVc{OTxxYU6=
AML-193 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LFTVczKGh? MmTpSG1UVw>? M1PIOWlEPTB;MD60OlIhyrFiMD6wOlAh|ryP NYTKT451RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OVk4OzFpPkK1OlU6PzNzPD;hQi=>
HL-60 MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGS3UWw4OiCq MmTtSG1UVw>? NXH2N|lvUUN3ME2wMlAxOSEEsTCwMlAxODJizszN M4HZTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O|MyLz5{NU[1PVc{OTxxYU6=
ML-2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rU[|czKGh? MXPEUXNQ NUPxSWluUUN3ME2wMlAxQSEEsTCwMlAxOiEQvF2= M2XBT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O|MyLz5{NU[1PVc{OTxxYU6=
OCI/AML3 MnG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXu3NkBp M4TqUWROW09? MV3JR|UxRTBwMEGxJOKyKDBwMECyJO69VQ>? NH\lPXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
HEL NH\x[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvFRWY4OiCq M4K0WWROW09? MY\JR|UxRTBwNUW5JOKyKDBwMEO4JO69VQ>? MoT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUm3N|EoRjJ3NkW5O|MyRC:jPh?=
ME-1 M1[0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUi3NkBp MmHPSG1UVw>? M1jkZWlEPTB;MD62PFQhyrFiMD6xO|kh|ryP M3HF[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O|MyLz5{NU[1PVc{OTxxYU6=
THP-1 NGfsUmpCeG:ydH;zbZMhSXO|YYm= NWGzUJBoOcLizszN M3fyNlczKGh? MUHEUXNQ NETQdmJqdmS3Y3XzJIFxd3C2b4Ppdy=> NYKw[VFkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OVk4OzFpPkK1OlU6PzNzPD;hQi=>
M-07e M1L4SWZ2dmO2aX;uJGF{e2G7 MWew5qCUOcLizszN MWG3NkBp Mlr1SG1UVw>? MVrpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw M4\W[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O|MyLz5{NU[1PVc{OTxxYU6=
THP-1 MlXsSpVv[3Srb36gRZN{[Xl? NHLrZ|Qx6oDVMdMg{txO MkfRO|IhcA>? NXHVWm9NTE2VTx?= NX70ZohQcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N|E9N2F-
CMK MXPGeY5kfGmxbjDBd5NigQ>? NULXXHN[OOLCk{JCpO69VQ>? MUG3NkBp MY\EUXNQ MY\pcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw M4DreVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O|MyLz5{NU[1PVc{OTxxYU6=
AML-193 NVjpPIZ1TnWwY4Tpc44hSXO|YYm= NFvHWXcx6oDVMdMg{txO MoTCO|IhcA>? NHixNFZFVVOR MlLnbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDTeZJ3cX[rbh?= M2r5[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O|MyLz5{NU[1PVc{OTxxYU6=
Kasumi-1 MWrGeY5kfGmxbjDBd5NigQ>? MnrRNQKBmzIEoN88US=> MnLhO|IhcA>? NXPsUFVHTE2VTx?= MWDpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N|E9N2F-
MV4-11 MX7GeY5kfGmxbjDBd5NigQ>? MWGw5qCUOcLizszN MlnUO|IhcA>? MoTpSG1UVw>? MYjpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw NGXMOoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
MUG-Chor  MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXiwMVUh|ryP MXGyOE81QCCq MYPJR|UxRTdwMEZihKlvVSCob4KgOFhp MnnLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NECxPFUoRjJ3NkSwNVg2RC:jPh?=
U-CH1  MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVuwMVUh|ryP M3fReFI1NzR6IHi= NEOwXHpKSzVyPUmuNFPjiImwTTDmc5IhPDiq MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ2MEG4OUc,OjV4NECxPFU9N2F-
KATOIII MoDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVexNE8zOCCwTR?= NYfuflNDPDhiaB?= MU\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NILVdGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[zOVA2PSd-MkW2N|UxPTV:L3G+
AGS  NHL6N3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXqxNE8zOCCwTR?= M{LnUlQ5KGh? Mlv5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Mn\0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4M{WwOVUoRjJ3NkO1NFU2RC:jPh?=
SACC-83 MWjGeY5kfGmxbjDBd5NigQ>? MXO1JI5O MmDEOFghcA>? MXzk[YNz\WG|ZYOgcpVkdGWjcjDlfJBz\XO|aX;uJI9nKEiLRj2x{tE> NV3mdpoxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0PFU3OzVpPkK1OFg2PjN3PD;hQi=>
INA-6 M121O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzMc5MxNTVyMDDuUS=> MkfaOFghcA>? MVjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NInuc3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5Olk4QCd-MkWyPVY6Pzh:L3G+
U-266 NEfK[GVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{G0dVAuPTByIH7N M3\BbVQ5KGh? M4faTIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NWPIOHN{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVY6PzhpPkK1Nlk3QTd6PD;hQi=>
MOLP-8 M3PpcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVGwMVUxOCCwTR?= M3zNPFQ5KGh? M{P2[4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ7Nkm3PEc,OjV{OU[5O|g9N2F-
HG-1 NETXepVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXOwMVUxOCCwTR?= NYj0ZmE2PDhiaB?= NXf3V|JocW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ7Nkm3PEc,OjV{OU[5O|g9N2F-
NCI-H929 MmjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXGwMVUxOCCwTR?= NHHpU2c1QCCq NIX0dYRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MnflQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OU[5O|goRjJ3Mkm2PVc5RC:jPh?=
OPM-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUOwMVUxOCCwTR?= MXu0PEBp NV\xXnRjcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1[zR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mkm2PVc5Lz5{NUK5Olk4QDxxYU6=
L-363 M3jaZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXqWokxNTVyMDDuUS=> NFrvbmw1QCCq MmPtbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ7Nkm3PEc,OjV{OU[5O|g9N2F-
MOLP-2 NIPqXWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHZZYF1OC13MECgcm0> M{DWWlQ5KGh? NHnSSJJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NVfTW4RHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVY6PzhpPkK1Nlk3QTd6PD;hQi=>
KMS-12-BM NFnoepFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3T5fFAuPTByIH7N NHn2XHE1QCCq NUnqO5k3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2HSSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mkm2PVc5Lz5{NUK5Olk4QDxxYU6=
SK-MM-2 Mk\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDEdZVFOC13MECgcm0> MkfROFghcA>? NYSye21zcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MkTyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OU[5O|goRjJ3Mkm2PVc5RC:jPh?=
U-266 Mn3IRZBweHSxc3nzJGF{e2G7 MnPJNE02OCCwTR?= NXfUUGRROjRiaB?= MUDpcoR2[2W|IHHwc5B1d3Orcx?= M{LoV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mkm2PVc5Lz5{NUK5Olk4QDxxYU6=
INA-6  MmC0RZBweHSxc3nzJGF{e2G7 M1LqZVAuPTBibl2= M1\0T|I1KGh? NX\DUWJCcW6mdXPld{BieG:ydH;zbZM> MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ7Nkm3PEc,OjV{OU[5O|g9N2F-
MCF7 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPTO|IhcA>? NW\VXolbUUN3ME2xN{DDuSB4IH7N NGL5VnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKyNFIzPSd-MkWyNlAzOjV:L3G+
MCF7-TamR6 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrWR4Z1PzJiaB?= NXzOdHRLUUN3ME24JOKyKDZibl2= M{XMWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkKwNlI2Lz5{NUKyNFIzPTxxYU6=
MCF7-TamR7 NGP5WmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[3NkBp M{DUdGlEPTB;ODFCtUA{KG6P MnXOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MkCyNlUoRjJ3MkKwNlI2RC:jPh?=
MCF7-TamR8 NGDKR3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fvR|czKGh? NHXzZo5KSzVyPUG1JOKyKDZibl2= NXP3ZWVbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNlAzOjVpPkK1NlIxOjJ3PD;hQi=>
MCF7-TamC3 M{LDSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWq3NkBp MVrJR|UxRTZiwsGgN{BvVQ>? NEC3[4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKyNFIzPSd-MkWyNlAzOjV:L3G+
MCF7-TamC6 NYj5THpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLiO|IhcA>? M3r3W2lEPTB;NjFCtUAxNjFibl2= MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ{MEKyOUc,OjV{MkCyNlU9N2F-
MDA-MB-231 M17YUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEja[IU4OiCq M2jGWmlEPTB;NTFCtUAyKG6P M4H6[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkKwNlI2Lz5{NUKyNFIzPTxxYU6=
SK-BR-3 NGHsfZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYq1d5o{PzJiaB?= MlLhTWM2OD15INMxJFAvOyCwTR?= NFHqdWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKyNFIzPSd-MkWyNlAzOjV:L3G+
Eca109 Mk\SSpVv[3Srb36gRZN{[Xl? MlvnNU02OCCwTR?= M2nYTlQ5KGh? NY\aNZhHTE2VTx?= MkPSd5VxeHKnc4Pld{B{fXK4aY\pckBmgHC{ZYPzbY9vKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MkLhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzM{mzPVUoRjJ3MUO5N|k2RC:jPh?=
TE13 M2Pm[mZ2dmO2aX;uJGF{e2G7 MXKxMVUxKG6P NXyzOpBoPDhiaB?= M1;scWROW09? NX;mXIJse3WycILld5NmeyC|dYL2bZZqdiCneIDy[ZN{cW:wIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NU\aUHVwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxN|k{QTVpPkK1NVM6Ozl3PD;hQi=>
Eca109 NYLrfGZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLM[oQxNTFyMDDuUS=> NFjId5UzPC92ODDo MWLEUXNQ M4PFO4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M{POXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUO5N|k2Lz5{NUGzPVM6PTxxYU6=
TE13 NI\hbFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYmwMVExOCCwTR?= MYGyOE81QCCq MUHEUXNQ NITuNWFl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= Ml;NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzM{mzPVUoRjJ3MUO5N|k2RC:jPh?=
MT-3 NH\RRnhMcW6jc3WgRZN{[Xl? MoT1O|IhcA>? MVvEUXNQ MkW1TWM2OD1{Lki2JOKyKDBwNUSgcm0h\m:{IFTSOEBmgHC{ZYPzbY9v NYKyOXRiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OlY2QDVpPkK0PFY3PTh3PD;hQi=>
MDA-MB-468 MlHwT4lv[XOnIFHzd4F6 NIr0XoM4OiCq Mn3lSG1UVw>? NIDxOIxKSzVyPUCuNVEhyrFiMD6wNUBvVSCob4KgSHI1KGW6cILld5Nqd25? NYfUW4JURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OlY2QDVpPkK0PFY3PTh3PD;hQi=>
SUM-159 Ml7yT4lv[XOnIFHzd4F6 NVO0U4Z7PzJiaB?= NIf5O|VFVVOR M1zsU2lEPTB;MT63NkDDuSByLkOzJI5OKG[xcjDEVlQh\XiycnXzd4lwdg>? NYLi[YR{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OlY2QDVpPkK0PFY3PTh3PD;hQi=>
MT-3 MVTLbY5ie2ViQYPzZZk> M2L5S|czKGh? NHvUZWdFVVOR NYDpVHdTUUN3ME21OE4yOSEEsTC0MlMzKG6PIH\vdkBFWjViZYjwdoV{e2mxbh?= MnLJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6Nk[1PFUoRjJ2OE[2OVg2RC:jPh?=
MDA-MB-468 MlH0T4lv[XOnIFHzd4F6 NGPZbIk4OiCq NIHZdXlFVVOR Mn\NTWM2OD1yLkC3JOKyKDBwMEKgcm0h\m:{IFTSOUBmgHC{ZYPzbY9v NXn5e25bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OlY2QDVpPkK0PFY3PTh3PD;hQi=>
SUM-159 MlLYT4lv[XOnIFHzd4F6 MoPTO|IhcA>? MVrEUXNQ NYjUelZHUUN3ME22PU41KMLzIESuNlMhdk1iZn;yJGRTPSCneIDy[ZN{cW:w M1XGTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OE[2OVg2Lz5{NEi2OlU5PTxxYU6=
MT-3 + NAC MV7LbY5ie2ViQYPzZZk> MoTTO|IhcA>? MkG1SG1UVw>? MXvJR|UxRTV4LkKgxtEhOi5yNzDuUUBnd3JiRGK1JIV5eHKnc4Ppc44> MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh4NkW4OUc,OjR6Nk[1PFU9N2F-
MT-3 + SB203580 M{TMZWtqdmG|ZTDBd5NigQ>? NILQb2M4OiCq M4XGeGROW09? MV\JR|UxRTN6LkSxJOKyKDVwMEKgcm0h\m:{IFTSOUBmgHC{ZYPzbY9v NVrL[495RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OlY2QDVpPkK0PFY3PTh3PD;hQi=>
DB MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TxbFExKG6P MmTwNlQhcA>? NFLyWlhFVVOR MYLpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36= NUHDR4RjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PFY2QTVpPkK0OFg3PTl3PD;hQi=>
SU-DHL-8 NUm5PYR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTENVAhdk1? MWWyOEBp Ml[zSG1UVw>? M3;rUolvcGmkaYTzJINmdGxicILvcIln\XKjdHnvci=> MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR6NkW5OUc,OjR2OE[1PVU9N2F-
WSU-DLCL2 NH7EfmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLq[FIyOCCwTR?= MUCyOEBp MnXDSG1UVw>? Ml:wbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;u NXXxOmNuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PFY2QTVpPkK0OFg3PTl3PD;hQi=>
ACC-2 NXnMRZptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvTVmc{OC1zMECgcm0> NVPNPHdHOjRiaB?= MlP6bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NFrodVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO3NFk6PSd-MkSzO|A6QTV:L3G+
ACC-2 NHPEZ3JCeG:ydH;zbZMhSXO|YYm= M3PkVlAuOjBibl2= NYHsUYl5OjRiaB?= Mm[1bY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NVrxfYtxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzO|A6QTVpPkK0N|cxQTl3PD;hQi=>
ACC-2 MV3GeY5kfGmxbjDBd5NigQ>? MlPoNE0zOCCwTR?= M4rOTVI1KGh? Mm\SbY5kemWjc3XzJJRp\SClb372[ZJ{cW:wIH;mJGxEO0lidH:gUGM{UUl? NVfGSWVlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzO|A6QTVpPkK0N|cxQTl3PD;hQi=>
BFTC905 NIP5VJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M165blAuOTByMDDuUS=> NI\YR|c1QCCqwrC= NUXlcm82TE2VTx?= MmHaTWM2OD1{MDDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7N{[0OEc,OjR{OUe2OFQ9N2F-
T24 M4LPR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPxWJoxNTFyMECgcm0> NHnDWVE1QCCqwrC= MUHEUXNQ NXjDToZvUUN3ME2yNEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M2\PUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mkm3OlQ1Lz5{NEK5O|Y1PDxxYU6=
TSGH8301  NETMNIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHqNE0yODByIH7N NFjIeYQ1QCCqwrC= MY\EUXNQ M2ixeWlEPTB;MkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M1nkNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mkm3OlQ1Lz5{NEK5O|Y1PDxxYU6=
BFTC909 M2DKR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PZRlAuOTByMDDuUS=> NI\oOHM1QCCqwrC= MX3EUXNQ M1PEb2lEPTB;MkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NXfRO4ZNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVc3PDRpPkK0Nlk4PjR2PD;hQi=>
BFTC905 MkLZRZBweHSxc3nzJGF{e2G7 MlvJNlAhdk1? NV;HbHdPPDhiaB?= MWXEUXNQ MUHpcoR2[2W|IHHwc5B1d3Orcx?= NWfQd2szRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVc3PDRpPkK0Nlk4PjR2PD;hQi=>
BFTC905 Ml63SpVv[3Srb36gRZN{[Xl? NGGxcnMzOCCwTR?= NI\ofGg1QCCq NVTmSII6TE2VTx?= M4TuToRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBNSzOELVnJ M2X0VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mkm3OlQ1Lz5{NEK5O|Y1PDxxYU6=
A2780p Ml74SpVv[3Srb36gRZN{[Xl? MlfWNE0yODBibl2= NWTtR4VoOjRiaB?= MXPEUXNQ NUfTcJplcW6mdXPld{BUfXK4aY\pckBld3ewcnXneYxifGmxbtMg MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ4Mki3OUc,OjR{NkK4O|U9N2F-
A2780cis MXvGeY5kfGmxbjDBd5NigQ>? NXuxRmp7OC1zMECgcm0> M4raXlI1KGh? MkXoSG1UVw>? MmLBbY5lfWOnczDTeZJ3cX[rbjDkc5dvemWpdXzheIlwdsLi NGPEd5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK2Nlg4PSd-MkSyOlI5PzV:L3G+
A2780p M2\kVGFxd3C2b4Ppd{BCe3OjeR?= NVqz[XZEPS1zMECgcm0> NWr2dWlCOjRxNEigbC=> MVHEUXNQ M3y0VYlv[3KnYYPld{BieG:ydH;zbZMhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NFnwNnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK2Nlg4PSd-MkSyOlI5PzV:L3G+
A2780cis M1rocmFxd3C2b4Ppd{BCe3OjeR?= MVe1MVExOCCwTR?= NH\lR3AzPC92ODDo MYrEUXNQ MlTpbY5kemWjc3XzJIFxd3C2b4Ppd{BqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ4Mki3OUc,OjR{NkK4O|U9N2F-
SH-SY5Y MYXBdI9xfG:|aYOgRZN{[Xl? NWfOW3BNOS9zMD:xNFAhyrWP MmrNO|IhcA>? NVrlRnRqTE2VTx?= NHnsRo9qdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M33pV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkW0OVYxLz5{NEK1OFU3ODxxYU6=
HL-60 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fZeVczyqCq NHj0cnJFVVOR Ml7hTWM2OD1yLkOgcm0> M4TRVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG4PFYzLz5{M{[xPFg3OjxxYU6=
U937  NYLtRmdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjt[|U4OsLiaB?= MkDzSG1UVw>? M13j[mlEPTB;MD64JI5O Mo[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUi4OlIoRjJ|NkG4PFYzRC:jPh?=
HL-60  NHuxPZVHfW6ldHnvckBCe3OjeR?= MlXsNeKh|ryP MkX3Ok8yOi9{NDDo NF7XZWpFVVOR M3nlR4lvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJJN2en[rdnnu NW\WWoZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVg5PjJpPkKzOlE5QDZ{PD;hQi=>
U937  NF34[|BHfW6ldHnvckBCe3OjeR?= NF;WUZcyyqEQvF2= MlTTOk8yOi9{NDDo MYPEUXNQ M{Hhc4lvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJJN2en[rdnnu MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzOEi2Nkc,OjN4MUi4OlI9N2F-
HL-60 NIrr[XlCeG:ydH;zbZMhSXO|YYm= NYW0RphrOC5zL{Gg{txO M4rXOVghcA>? NF\JXlBFVVOR MXfpcoR2[2W|IHHwc5B1d3Orcx?= MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzOEi2Nkc,OjN4MUi4OlI9N2F-
Sk-NEP-1  MnjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYCxMVExODByIH7N MlK3NlQhcA>? M3L4VWROW09? NGjQV2lKSzVyPUGwNEBvVQ>? MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ4N{[5PUc,OjN{Nke2PVk9N2F-
SK-NEP-1  M3O4T2Fxd3C2b4Ppd{BCe3OjeR?= MVy1NE8yODBibl2= MWexNk8zPCCq MX;EUXNQ M365U4lv\HWlZYOgZZBweHSxc3nz NWfucGF{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOlc3QTlpPkKzNlY4Pjl7PD;hQi=>
TC-32 NG\kU|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYH6fFl4OC5zLUGwNFAhdk1? MVTFR|UxRTNwMDDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl4MUe2N{c,OjJ7NkG3OlM9N2F-
TC-71 NVnqWphET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIe4O|MxNjFvMUCwNEBvVQ>? M1XRN2VEPTB;NT63JI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M2T4cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OU[xO|Y{Lz5{Mkm2NVc3OzxxYU6=
SK-ES-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVqzZVFFOC5zLUGwNFAhdk1? NInpVZlGSzVyPUKuPEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NF:1VGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mkm2NVc3Oyd-MkK5OlE4PjN:L3G+
RD-ES NV3QVpJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzZNE4yNTFyMECgcm0> Mn:0SWM2OD14LkKgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NG\1PFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mkm2NVc3Oyd-MkK5OlE4PjN:L3G+
HEK293 M2flPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDmNE4yNTFyMECgcm0> NHrUeXhGSzVyPUKzMlAhdk1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NGHp[3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mkm2NVc3Oyd-MkK5OlE4PjN:L3G+
M059J NWX5RoxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzjd2wxNTVyIH7N NGXqeGU1QCCq M4jGNolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NF;aOIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke3NFEyOCd-MkK3O|AyOTB:L3G+
M059K NYPM[IlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjUdW1FOC13MDDuUS=> MnnaOFghcA>? NH76VG9qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NXrJZ2VTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3O|AyOTBpPkKyO|cxOTFyPD;hQi=>
M059J NIfJSZpCeG:ydH;zbZMhSXO|YYm= MVWzNEBvVQ>? M33mTVI1KGh? MlLrbY5lfWOnczDhdI9xfG:|aYO= Mn;pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5N{CxNVAoRjJ{N{ewNVExRC:jPh?=
M059K MV7BdI9xfG:|aYOgRZN{[Xl? M2SxUVMxKG6P NHXoRWgzPCCq NULmfmIxcW6mdXPld{BieG:ydH;zbZM> MnfUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5N{CxNVAoRjJ{N{ewNVExRC:jPh?=
PANC-1 MoH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjGS|YxNjBzLUGwNFAhdk1? NGLFWGo1QCCq Mof4TWM2OD1|Lk[5JI5O MoTEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5MkO4O|EoRjJ{N{KzPFcyRC:jPh?=
MIAPaCa-2 NVLadmY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7QNE4xOS1zMECwJI5O MYK0PEBp NWn1fWNkUUN3ME2yPU4{PiCwTR?= MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd{M{i3NUc,OjJ5MkO4O|E9N2F-
BxPC-3 M2K3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUKwMlAyNTFyMECgcm0> MknkOFghcA>? M1KwPGlEPTB;M{CuNlYhdk1? MnmxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5MkO4O|EoRjJ{N{KzPFcyRC:jPh?=
PANC-1 NYfxVXBsTnWwY4Tpc44hSXO|YYm= Mo\5NE0yODByIH7N M3XnfVI1KGh? MV\pcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGjJRXAh[W6mIIP1dpZqfmmwIHX4dJJme3Orb36= M4jyXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{KzPFcyLz5{MkeyN|g4OTxxYU6=
MIAPaCa-2 MoHnSpVv[3Srb36gRZN{[Xl? NIr1UpIxNTFyMECgcm0> NF;DO|AzPCCq NH;CUXlqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHhKSVBiYX7kJJN2en[rdnnuJIV5eHKnc4Ppc44> MoW2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5MkO4O|EoRjJ{N{KzPFcyRC:jPh?=
BxPC-3 M1;DPGZ2dmO2aX;uJGF{e2G7 MVewMVExODBibl2= M4TFelI1KGh? MXnpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGjJRXAh[W6mIIP1dpZqfmmwIHX4dJJme3Orb36= MnnOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5MkO4O|EoRjJ{N{KzPFcyRC:jPh?=
RPMI-7951 NYG3OWl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj6UHBiT0l3ME2zMlIhdk1? NWnaUHA6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3N|c2ODJpPkKxO|M4PTB{PD;hQi=>
SK-MEL-5 NEPmNJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2S4XWdKPTB;ND6yJI5O MoXXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5M{e1NFIoRjJzN{O3OVAzRC:jPh?=
A375 NEHjXpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLoSJR4T0l3ME22MlMhdk1? MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd|N{WwNkc,OjF5M{e1NFI9N2F-
SK-MEL-28 NX21XXRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHHTVUxRTdwNjDuUS=> MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd|N{WwNkc,OjF5M{e1NFI9N2F-
SK-MEL-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\BOFNDT0l3ME2xNUBvVQ>? M33sXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{O3OVAzLz5{MUezO|UxOjxxYU6=
DB NUW5VXhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDjOFjDqGh? NIf6TpRIUTVyPUOuOUBvVQ>? NVrXWo5VRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyN|c2ODhpPkKxNlM4PTB6PD;hQi=>
Pfeiffer MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXOyT4pjPDkEoHi= M2DRPWdKPTB;Mz65JI5O Mkm0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{M{e1NFgoRjJzMkO3OVA5RC:jPh?=
SU-DHL-5 NEfUUlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrRVXQ1QMLiaB?= MWHHTVUxRTBwMkOgcm0> NFHS[VY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUKzO|UxQCd-MkGyN|c2ODh:L3G+
SU-DHL-8 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHTOFjDqGh? M33hSWdKPTB;MT60JI5O NH;ENo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUKzO|UxQCd-MkGyN|c2ODh:L3G+
WSU-DLCL-2 MlXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf2OFjDqGh? MVjHTVUxRTFwNDDuUS=> MnLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{M{e1NFgoRjJzMkO3OVA5RC:jPh?=
A549 M1zrSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWLHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDBOVQ6KGOnbHzzMEBKSzVyPUCuNFE{PM7:TR?= MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDhzNEO3OEc,Ojh6MUSzO|Q9N2F-
DU145 NWLBRplqS3m2b4TvfIlkcXS7IHHzd4F6 NYrGZ3FVS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYomgUXRVKGG|c3H5MEBGSzVyPUCuNFE{QM7:TR?= NVvUWHNjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3O|Q1OjZpPkK4O|c1PDJ4PD;hQi=>
PC3 NFjoXpVEgXSxdH;4bYNqfHliYYPzZZk> NWHMdY1CS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KGK7IF3UWEBie3OjeTygSWM2OD1yLkC5Nu69VQ>? NWns[lFzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3O|Q1OjZpPkK4O|c1PDJ4PD;hQi=>
A549 NH:5S2dHfW6ldHnvckBie3OjeR?= MWXJcohq[mm2aX;uJI9nKFCDS{GgbY4hcHWvYX6gRVU1QSClZXzsd{whUUN3ME2wMlXPxE1? NGnmTG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEixOFM4PCd-Mki4NVQ{PzR:L3G+
Assay
Methods Test Index PMID
Western blot Survivin / XIAP / Caspase-7 / Caspase-9 / Caspase-3 / Cleaved Caspase-8 / PARP ; β-catenin / c-Myc / Cyclin D1 / CD44 ; p-STAT3 / STAT3 26771139 22723871
Immunofluorescence EGFR ; PARP-1 / PAR 22723871 26090615
Growth inhibition assay Cell viability 29636860
In vivo YM155 completely inhibits the tumor growth of PC-3 s.c. xenografted prostate tumors at doses of 3 and 10 mg/kg, without body weight loss and blood cell count decrease. Pharmacokinetic analysis shows that YM155 is highly distributed to tumor tissue. Moreover, YM155 shows 80% TGI at a dose of 5 mg/kg in PC-3 orthotopic xenografts. [1] The combination therapy with YM155 and γ-radiation shows great antitumor activity against H460 or Calu6 xenografts in nude mice. [2]

Protocol (from reference)

Kinase Assay:

[1]

  • Promoter-luciferase reporter assay:

    A 2,767-bp sequence of human survivin gene promoter is isolated from human genomic DNA by PCR using Pyrobest polymerase and the following primers: 5

Cell Research:

[1]

  • Cell lines: Hormone refractory prostate cancer cell lines (PC-3, PPC-1, DU145, TSU-Pr1 and 22Rv1) and malignant melanoma cell lines (SK-MEL-5 and A375)
  • Concentrations: ~ 100 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded in 96-well plates at a density of 5-40 × 103. YM155 is dissolved in DMSO and added to cells for 48 hours. Then the cell count is determined by sulforhodamine B assay.

Animal Research:

[1]

  • Animal Models: PC-3 s.c. (orthotopic) xenografts in male nude mice (BALB/c nu/nu)
  • Dosages: 5 mg/kg
  • Administration: Subcutaneous injection as a 3-day continuous infusion per week for 3 weeks by an implanted micro-osmotic pump

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.

30 mg/mL

Chemical Information

Molecular Weight 443.29
Formula

C20H19BrN4O3

CAS No. 781661-94-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=[N+](C2=C(N1CCOC)C(=O)C3=CC=CC=C3C2=O)CC4=NC=CN=C4.[Br-]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01023386 Completed Drug: YM155 Cancer Astellas Pharma Inc November 2009 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) supplier | purchase YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) cost | YM155 (Sepantronium Bromide) manufacturer | order YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) distributor